A Phase 2 interventional study of Carboplatin and Paclitaxel in Carcinoma and Non-Squamous Non-Small-Cell Lung Cancer, sponsored by UCB Pharma. Completed at 22 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing carboplatin in Carcinoma — 1 open to participants now, 5 under way, 3 of them phase 3. Carboplatin · Carcinoma.
Among the 22 studies testing carboplatin in Carcinoma, this one is the 8th largest by enrollment, is the only one that started in 2005, is one of 15 in phase 2, and was the 2nd registered.
736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.
Browse Carcinoma studies →1 of the 22 studies testing carboplatin in Carcinoma is open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
By country, each count listing its studies:
Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →
Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 4 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 49 across 571 interventional studies indexed under Carcinoma.
Median enrollment 41 across the 22 interventional studies. Of the 17 that completed or were terminated, 12 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
UCB S.A. has 1 study filed under Carcinoma — fewer than ten, so there is no comparison to draw.
2 of the studies testing carboplatin in Carcinoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT06317311GlaxoSmithKlineA Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer | 2026-12-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing carboplatin in Carcinoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
This is a two part study to investigate the safety and anti-tumour effects of standard chemotherapy, plus an investigational drug (CDP791), in patients with advanced non small cell lung cancer.
In part one, patients receive carboplatin and paclitaxel chemotherapy together with one of 2 doses of CDP791. The main aim of this part is to investigate safety and tolerability of carboplatin/paclitaxel plus CDP791.
If part one confirms that the combination of drugs is safe and well tolerated, 156 patients will enter part 2. They will be randomized to receive either carboplatin/paclitaxel (C/P) alone, or C/P plus one of 2 doses of CDP791. The main aim of this part of the study is to compare the anti-tumor effects of CDP791 plus C/T with those of C/T alone. Participants will receive up to six cycles of chemotherapy with or without CDP791. Those whose disease stabilizes, or responds, will be eligible to continue to receive CDP791. Participants in the C/T alone arm whose disease progresses will be eligible to receive CDP791 monotherapy.
Participants will be followed up longterm, so that survival can be measured.
Inclusion Criteria:
Inclusion Criteria:
Exclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carboplatin and paclitaxel alone.
Drug: Carboplatin · Drug: Paclitaxel
Carboplatin and paclitaxel plus CDP791 10mg/kg
Drug: Carboplatin · Drug: Paclitaxel · Drug: CDP791 10mg/kg · Drug: CDP791 20mg/kg
Carboplatin and paclitaxel plus CDP791 20mg/kg
Drug: Carboplatin · Drug: Paclitaxel · Drug: CDP791 10mg/kg · Drug: CDP791 20mg/kg
10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle. Each cycle to be repeated every three weeks for a maximum of six cycles.
Also known as: CBDCA, Paraplatin, JM-8, NSC 241240
6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
Also known as: Taxol, NSC #673089
CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
Tumor Response Rate (RR)
Participants are evaluated for response using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al; 2000). The tumor response rate is calculated as the total number of subjects whose best overall response is a complete response (CR)= disappearance of all target lesions; or a partial response (PR) = \>=30 % decrease in the sum of the longest diameter of target lesions, divided by the number of randomized subjects (RS): (CR + PR) / RS.
Time frame: 24 weeks
Progression Free Survival (PFS)
Progression free survival (PFS) is defined as time from date of randomization until the date progressive disease (PD) is first recorded or until death, whichever is first.
Time frame: Up to 57 weeks
Time to Treatment Failure
Time to treatment failure (TTF) is defined as the time from date of randomization until the date of progression, death or, for subjects who discontinued treatment for toxicity reason, their last dosing date, whichever occurs first.
Time frame: Up to 57 weeks
Overall Survival
Overall survival is defined as the time from date of randomization until the date of death.
Time frame: Up to 57 weeks
Duration of Overall Response
The duration of overall response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR), whichever is recorded first, until the first date of documented progressive disease or death.
Time frame: Up to 57 weeks
Time to Response
Time to response is defined as the time from the first dose of study therapy until measurement criteria are first met for complete response or partial response (whichever is recorded first).
Time frame: Week 24
The study started to enroll patients in August 2005 and concluded in June 2009. Across Part I (dose escalation) and Part II (Open Label randomized) of the study, 165 subjects were analyzed. Part II was opened for 156 response-evaluable subjects.
| Milestone | Carboplatin/Paclitaxel | Carboplatin/Paclitaxel/CDP791 10mg | Carboplatin/Paclitaxel/CDP791 20mg |
|---|---|---|---|
| Started | 50 | 56 | 59 |
| Part ii | 50 | 53 | 53 |
| Completed | 22 | 34 | 39 |
| Not completed | 28 | 22 | 20 |
| Withdrew: Adverse event | 9 | 4 | 5 |
| Withdrew: Death | 1 | 3 | 3 |
| Withdrew: Lack of efficacy | 4 | 5 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 | 0 |
| Withdrew: Progression of disease | 6 | 8 | 4 |
| Withdrew: Investigator decision | 0 | 0 | 1 |
| Withdrew: Patient condition worsened | 1 | 0 | 0 |
| Milestone | Carboplatin/Paclitaxel | Carboplatin/Paclitaxel/CDP791 10mg | Carboplatin/Paclitaxel/CDP791 20mg |
|---|---|---|---|
| Started | 15 | 29 | 34 |
| Part ii | 13 | 26 | 29 |
| Completed | 0 | 0 | 0 |
| Not completed | 15 | 29 | 34 |
| Withdrew: Adverse event | 1 | 0 | 5 |
| Withdrew: Death | 2 | 0 | 1 |
| Withdrew: Lack of efficacy | 7 | 16 | 10 |
| Withdrew: Protocol violation | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 |
| Withdrew: Progression of disease | 5 | 11 | 12 |
| Withdrew: Patient decision | 0 | 1 | 1 |
| Withdrew: Study personel decision | 0 | 0 | 1 |
Participants are evaluated for response using Response Evaluation Criteria in Solid Tumors (RECIST) (Therasse P et al; 2000). The tumor response rate is calculated as the total number of subjects whose best overall response is a complete response (CR)= disappearance of all target lesions; or a partial response (PR) = \>=30 % decrease in the sum of the longest diameter of target lesions, divided by the number of randomized subjects (RS): (CR + PR) / RS.
| percentage of participants | Carboplatin/Paclitaxel (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) | Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) |
|---|---|---|---|---|
| Complete responder | 0 | 0 | 0 | 0 |
| Partial responder | 20 | 26.4 | 22.6 | 30.2 |
Progression free survival (PFS) is defined as time from date of randomization until the date progressive disease (PD) is first recorded or until death, whichever is first.
| weeks | Carboplatin/Paclitaxel (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) | Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) |
|---|---|---|---|---|
| Progression Free Survival (PFS) | 24.14 (20.29 to 29.29) | 26.86 (24.43 to 30.14) | 26.86 (21.14 to 30.71) | 25.43 (24.29 to 30.43) |
Time to treatment failure (TTF) is defined as the time from date of randomization until the date of progression, death or, for subjects who discontinued treatment for toxicity reason, their last dosing date, whichever occurs first.
| weeks | Carboplatin/Paclitaxel (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) | Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) |
|---|---|---|---|---|
| Time to Treatment Failure | 13.21 (6.86 to 20.29) | 21.71 (18.14 to 24.71) | 18.43 (12.14 to 24.71) | 24.29 (18.14 to 27.00) |
Overall survival is defined as the time from date of randomization until the date of death.
| weeks | Carboplatin/Paclitaxel (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) | Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) |
|---|---|---|---|---|
| Overall Survival | 36.14 (27.14 to 64.14) | 47.14 (40.43 to 56.00) | 46.57 (38.57 to 59.86) | 47.57 (31.29 to 75.00) |
The duration of overall response is measured from the time measurement criteria are first met for complete response (CR) or partial response (PR), whichever is recorded first, until the first date of documented progressive disease or death.
| weeks | Carboplatin/Paclitaxel (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) | Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) |
|---|---|---|---|---|
| Duration of Overall Response | 21.14 (19.14 to NA) | 21.14 (16.86 to 22.43) | 21.14 (19.29 to NA) | 18.00 (16.71 to 22.43) |
Time to response is defined as the time from the first dose of study therapy until measurement criteria are first met for complete response or partial response (whichever is recorded first).
| weeks | Carboplatin/Paclitaxel (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 (Randomized Part II SjS) | Carboplatin/Paclitaxel/CDP791 10mg (Randomized Part II SS) | Carboplatin/Paclitaxel/CDP791 20mg (Randomized Part II SjS) |
|---|---|---|---|---|
| Time to Response | 8.57 (8.14 to 17.43) | 9.14 (8.36 to 16.64) | 11.86 (8.86 to 16.64) | 9.00 (8.21 to 15.29) |
Collected over Adverse events were collected from Visit 1 until Safety Follow-Up Visit (for up to 57 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Carboplatin/Paclitaxel (SS) | 30/50 (60%) | 18/50 (36%) | 44/50 (88%) |
| Carboplatin/Paclitaxel/CDP791 (SS) | 72/115 (62.6%) | 36/115 (31.3%) | 110/115 (95.7%) |
| Carboplatin/Paclitaxel/CDP791 10mg (SS) | 39/56 (69.6%) | 18/56 (32.1%) | 54/56 (96.4%) |
| Carboplatin/Paclitaxel/CDP791 20mg (SS) | 33/59 (55.9%) | 18/59 (30.5%) | 56/56 (100%) |
| Event | Carboplatin/Paclitaxel (SS) | Carboplatin/Paclitaxel/CDP791 (SS) | Carboplatin/Paclitaxel/CDP791 10mg (SS) | Carboplatin/Paclitaxel/CDP791 20mg (SS) |
|---|---|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/50 | 2/115 | 0/56 | 2/59 |
| AnaemiaBlood and lymphatic system disorders | 4/50 | 6/115 | 2/56 | 4/59 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/50 | 5/115 | 2/56 | 3/59 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 1/50 | 3/115 | 0/56 | 3/59 |
| Oedema peripheralGeneral disorders | 2/50 | 0/115 | 0/56 | 0/59 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/50 | 0/115 | 0/56 | 0/59 |
| Weight decreasedInvestigations | 1/50 | 3/115 | 2/56 | 1/59 |
| FatigueGeneral disorders | 1/50 | 2/115 | 0/56 | 2/59 |
| Cardiac failureCardiac disorders | 1/50 | 1/115 | 0/56 | 1/59 |
| Cardiopulmonary failureCardiac disorders | 1/50 | 1/115 | 1/56 | 0/59 |
| Event | Carboplatin/Paclitaxel (SS) | Carboplatin/Paclitaxel/CDP791 (SS) | Carboplatin/Paclitaxel/CDP791 10mg (SS) | Carboplatin/Paclitaxel/CDP791 20mg (SS) |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 15/50 | 42/115 | 19/56 | 23/56 |
| AlopeciaSkin and subcutaneous tissue disorders | 18/50 | 38/115 | 19/56 | 19/56 |
| AnaemiaBlood and lymphatic system disorders | 17/50 | 35/115 | 17/56 | 18/56 |
| LeukopeniaBlood and lymphatic system disorders | 4/50 | 23/115 | 14/56 | 9/56 |
| FatigueGeneral disorders | 10/50 | 16/115 | 9/56 | 7/56 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/50 | 19/115 | 8/56 | 11/56 |
| NauseaGastrointestinal disorders | 7/50 | 16/115 | 6/56 | 10/56 |
| AnorexiaMetabolism and nutrition disorders | 6/50 | 18/115 | 8/56 | 10/56 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/50 | 14/115 | 4/56 | 10/56 |
| Bone painMusculoskeletal and connective tissue disorders | 1/50 | 15/115 | 6/56 | 9/56 |
Baseline Characteristics refer to all response-evaluable Part II subjects.
| Age, Categorical(Participants) | Carboplatin/Paclitaxel | Carboplatin/Paclitaxel/CDP791 10mg | Carboplatin/Paclitaxel/CDP791 20mg | Total Title |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 30 | 35 | 40 | 105 |
| >=65 years | 20 | 18 | 13 | 51 |
| Age, Continuous(years) | Carboplatin/Paclitaxel | Carboplatin/Paclitaxel/CDP791 10mg | Carboplatin/Paclitaxel/CDP791 20mg | Total Title |
|---|---|---|---|---|
| Mean | 61.58 ± 10.69 | 60.70 ± 10.01 | 58.25 ± 9.38 | 60.15 ± 10.06 |
| Sex: Female, Male(Participants) | Carboplatin/Paclitaxel | Carboplatin/Paclitaxel/CDP791 10mg | Carboplatin/Paclitaxel/CDP791 20mg | Total Title |
|---|---|---|---|---|
| Female | 20 | 21 | 29 | 70 |
| Male | 30 | 32 | 24 | 86 |
Ran from Aug 2005 to primary completion in Jun 2009, 46 months.
Results were first posted in Apr 2022, 12 years 9 months after primary completion.
Of 82 phase 2 interventional studies under Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 88. This study's 46 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Carboplatin · Paclitaxel